–

–

Financing

融资

by RA Capital Management

由 RA Capital Management 提供

to advance HEX17, its

推进 HEX17，其

lead intranasal

鼻内铅

preventative antiviral candidate, toward Phase 2b readiness

预防性抗病毒候选药物，迈向二期b临床试验准备阶段

–

–

– UK-based Pneumagen Ltd. reorganized to create US-based NorthLinks Bio, while

– 英国 Pneumagen Ltd. 重组，成立总部位于美国的 NorthLinks Bio，同时

maintaining research operations in St Andrews, Scotland –

在苏格兰圣安德鲁斯维持研究运营——

BOSTON

波士顿

,

，

June 23, 2026

2026年6月23日

/PRNewswire/ -- NorthLinks Bio, a clinical-stage biotechnology company developing broad-spectrum antiviral preventive medicines for respiratory viral infections, today announced both its launch and the completion of a $34 million financing by RA Capital Management. In conjunction with the financing, Pneumagen Ltd.

/PRNewswire/ -- NorthLinks Bio 是一家处于临床阶段的生物技术公司，致力于开发用于呼吸道病毒感染的广谱抗病毒预防药物。该公司今日宣布正式成立，并完成由 RA Capital Management 领投的 3400 万美元融资。伴随此次融资，Pneumagen Ltd.

has reorganized into US-based NorthLinks Bio, with continued research operations in St Andrews, Scotland..

已重组为总部位于美国的NorthLinks Bio公司，并在苏格兰圣安德鲁斯持续开展研究业务。

The financing will enable NorthLinks Bio to advance its lead intranasal prophylactic antiviral candidate, HEX17, toward Phase 2b readiness and fund continued development of its proprietary glycan-targeted platform for prevention and treatment of respiratory viral infections. Proceeds will also support HEX17 manufacturing and establish NorthLinks Bio's US operations to support future clinical development in influenza and other respiratory viral indications..

此次融资将使NorthLinks Bio能够推进其领先的鼻用预防性抗病毒候选药物HEX17，使其具备进入2b期临床试验的条件，并为其专有的靶向聚糖平台（用于预防和治疗呼吸道病毒感染）的持续开发提供资金。所得款项还将支持HEX17的生产，并建立NorthLinks Bio在美国的运营体系，以支持未来在流感及其他呼吸道病毒适应症方面的临床开发。

HEX17 is a convenient intranasal spray designed to provide broad-spectrum protection against respiratory virus infections by targeting sialic acid, a validated host receptor involved in multiple respiratory pathogens' entry into host cells. HEX17 is designed to prevent infections at the earliest stages and has the potential to maintain activity despite ongoing viral evolution and the emergence of new variants..

HEX17是一种便捷的鼻内喷雾剂，旨在通过靶向唾液酸（一种经证实的宿主受体，参与多种呼吸道病原体进入宿主细胞的过程）提供针对呼吸道病毒感染的广谱保护。HEX17旨在在感染的最早期阶段进行预防，并且即使病毒不断进化以及新变异株出现，仍有望保持其活性。

HEX17 has successfully completed Phase 1 and Phase 2a clinical studies, including an influenza human challenge study in which prophylactic administration resulted in an approximately 50% reduction in symptomatic influenza infection,  accompanied by reductions in symptom severity and viral shedding. This result is comparable to numbers observed in similar studies performed with approved influenza antivirals..

HEX17已顺利完成I期和IIa期临床研究，其中包括一项流感人体挑战研究。在该研究中，预防性给药使有症状的流感感染率降低了约50%，并伴随症状严重程度和病毒排出量的减少。这一结果与在类似研究中观察到的已获批流感抗病毒药物的数据相当。

HEX17 originated from NorthLinks Bio's glycan-targeted platform, which is based on engineered carbohydrate-binding modules (CBMs) designed to bind with high affinity to sialic acids present on the surface of respiratory epithelial cells. The platform has potential applications across multiple respiratory viruses and may support both prophylactic and therapeutic approaches..

HEX17 源自 NorthLinks Bio 的聚糖靶向平台，该平台基于经过工程化改造的碳水化合物结合模块（CBM），旨在与呼吸道上皮细胞表面存在的唾液酸高亲和力结合。该平台在多种呼吸道病毒领域具有潜在应用价值，并可能支持预防和治疗两种策略。

NorthLinks Bio has assembled an experienced leadership team to guide the company's next stage of growth and development led by Chief Executive Officer Fanny Cavalié, a Venture Partner at RA Capital's Raven healthcare incubator and previously Chief Strategy & Business Operations Officer at Foghorn Therapeutics..

NorthLinks Bio 已组建一支经验丰富的领导团队，以引领公司下一阶段的成长与发展。该团队由首席执行官 Fanny Cavalié 领导，她同时担任 RA Capital 旗下 Raven 医疗健康孵化器的风险合伙人，并曾出任 Foghorn Therapeutics 的首席战略与业务运营官。

'Respiratory viruses continue to represent a significant global health burden despite the availability of vaccines and antiviral therapies,' said Fanny Cavalié, CEO of NorthLinks Bio. 'We believe there is a substantial opportunity for a convenient, broad-spectrum intranasal prophylactic capable of providing continuous protection across influenza strains and potentially other respiratory viruses.

NorthLinks Bio 首席执行官 Fanny Cavalié 表示：“尽管已有疫苗和抗病毒疗法，呼吸道病毒仍然构成重大的全球健康负担。我们相信，一种能够提供针对多种流感毒株并可能涵盖其他呼吸道病毒的持续保护的便捷、广谱鼻内预防制剂存在巨大的市场机会。”

By targeting a validated host pathway, HEX17 is designed to provide broad protection that may remain resilient to viral evolution and support prophylactic use across respiratory virus seasons.'.

HEX17 通过靶向一条经验证的宿主通路，旨在提供广泛的保护作用，这种保护可能对病毒进化保持韧性，并支持在呼吸道病毒流行季节进行预防性使用。

Douglas Thomson, former CEO of Pneumagen, will transition to the NorthLinks Bio Board of Directors. 'I am excited for the next stage of growth and to continue to support the company through it,' said Thomson.

Pneumagen 前首席执行官道格拉斯·汤姆森将加入 NorthLinks Bio 董事会。“我对下一阶段的成长感到兴奋，并期待在此期间继续支持公司，”汤姆森表示。

In addition to Douglas Thomson and Fanny Cavalié, NorthLinks Bio's board comprises: Laura Tadvalkar, Managing Director at RA Capital; Mario Barro, Head of Infectious Diseases at RA Capital; Fenel Eloi, former COO of Cell Signaling Technology; and John Beadle, former CEO of PsiOxus Therapeutics.

除道格拉斯·汤姆森和范妮·卡瓦利埃外，NorthLinks Bio的董事会成员还包括：RA Capital管理董事劳拉·塔德瓦尔卡、RA Capital传染病部门负责人马里奥·巴罗、Cell Signaling Technology前首席运营官费内尔·埃洛伊，以及PsiOxus Therapeutics前首席执行官约翰·比德尔。

About NorthLinks Bio

关于北联生物

NorthLinks Bio is a clinical-stage biotechnology company developing broad-spectrum prophylactic therapies for respiratory viruses. The company's lead candidate, HEX17, is an intranasal prophylactic designed to prevent infection by targeting host-cell receptors involved in viral entry. Built on the company's proprietary glycan-targeted platform, NorthLinks Bio is advancing a strain-agnostic approach intended to provide protection against multiple respiratory viruses while maintaining activity despite viral evolution.

NorthLinks Bio 是一家处于临床阶段的生物技术公司，致力于开发针对呼吸道病毒的广谱预防性疗法。公司的核心候选产品 HEX17 是一种鼻用预防剂，旨在通过靶向参与病毒进入的宿主细胞受体来预防感染。基于公司专有的聚糖靶向平台，NorthLinks Bio 正在推进一种非株特异性的方法，旨在对多种呼吸道病毒提供保护，并在病毒进化过程中保持活性。

NorthLinks Bio is headquartered in Boston, Massachusetts, with research operations in St Andrews, Scotland. For more information, visit .

NorthLinks Bio 总部位于美国马萨诸塞州波士顿，并在苏格兰圣安德鲁斯设有研发机构。欲了解更多信息，请访问。

www.northlinksbio.com

www.northlinksbio.com

.

。

SOURCE Northlinks Bio

来源：Northlinks Bio

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示